166 related articles for article (PubMed ID: 22280117)
1. A potencial theranostic agent for EGF-R expression tumors: (177)Lu-DOTA-nimotuzumab.
Calzada V; Zhang X; Fernandez M; Diaz-Miqueli A; Iznaga-Escobar N; Deutscher SL; Balter H; Quinn TP; Cabral P
Curr Radiopharm; 2012 Oct; 5(4):318-24. PubMed ID: 22280117
[TBL] [Abstract][Full Text] [Related]
2. Preparation of
Pandey U; Kameswaran M; Gamre N; Dash A
J Labelled Comp Radiopharm; 2019 Apr; 62(4):158-165. PubMed ID: 30663095
[TBL] [Abstract][Full Text] [Related]
3. Design, preparation and biological evaluation of a
Behnammanesh H; Jokar S; Erfani M; Geramifar P; Sabzevari O; Amini M; Mazidi SM; Hajiramezanali M; Beiki D
Bioorg Chem; 2020 Jan; 94():103381. PubMed ID: 31662215
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation of
Hartimath SV; Alizadeh E; Solomon VR; Chekol R; Bernhard W; Hill W; Parada AC; Barreto K; Geyer CR; Fonge H
J Nucl Med; 2019 Aug; 60(8):1103-1110. PubMed ID: 30655327
[TBL] [Abstract][Full Text] [Related]
5. Clinical Dose Preparation of [
Menon SR; Mitra A; Chakraborty A; Tawate M; Sahu S; Rakshit S; Gaikwad S; Dhotre G; Damle A; Banerjee S
Cancer Biother Radiopharm; 2022 Jun; 37(5):384-402. PubMed ID: 35575711
[No Abstract] [Full Text] [Related]
6. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
7. Induction of different cellular arrest and molecular responses in low EGFR expressing A549 and high EGFR expressing A431 tumor cells treated with various doses of
Suman S; Priya R; Kameswaran M
Int J Radiat Biol; 2020 Sep; 96(9):1144-1156. PubMed ID: 32657634
[TBL] [Abstract][Full Text] [Related]
8. Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model.
Schmitt A; Bernhardt P; Nilsson O; Ahlman H; Kölby L; Forssell-Aronsson E
Cancer Biother Radiopharm; 2005 Apr; 20(2):231-6. PubMed ID: 15869461
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors.
Vera DR; Eigner S; Beran M; Henke KE; Laznickova A; Laznicek M; Melichar F; Chinol M
Cancer Biother Radiopharm; 2011 Jun; 26(3):287-97. PubMed ID: 21711096
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of radiolabelled nimotuzumab, a promising monoclonal antibody targeting the epidermal growth factor receptor.
Barta P; Laznickova A; Laznicek M; Vera DR; Beran M
J Labelled Comp Radiopharm; 2013 May; 56(5):280-8. PubMed ID: 24285372
[TBL] [Abstract][Full Text] [Related]
11. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin.
Yao Z; Zhang M; Axworthy DB; Wong KJ; Garmestani K; Park L; Park CW; Mallett RW; Theodore LJ; Yau EK; Waldmann TA; Brechbiel MW; Paik CH; Pastan I; Carrasquillo JA
Cancer Res; 2002 Oct; 62(20):5755-60. PubMed ID: 12384535
[TBL] [Abstract][Full Text] [Related]
12.
Scotognella T; Maccora D; Bruno I; Chinol M; Castagnola M; Collamati F; Mancini-Terraciano C; Morganti S; Bocci V; Camillocci ES; Rotili D; Cartoni A; Fratoddi I; Marini F; Venditti I; Faccini R; Giordano A
Curr Radiopharm; 2022; 15(1):32-39. PubMed ID: 33397277
[TBL] [Abstract][Full Text] [Related]
13. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
[TBL] [Abstract][Full Text] [Related]
14. Fab(nimotuzumab)-HYNIC-99mTc: Antibody Fragmentation for Molecular Imaging Agents.
Calzada V; García MF; Alonso-Martínez LM; Camachoc X; Goicochea E; Fernández M; Castillo AX; Díaz-Miqueli A; Iznaga-Escobar N; Montaña RL; Alonso O; Gambini JP; Cabral P
Anticancer Agents Med Chem; 2016; 16(9):1184-9. PubMed ID: 26961312
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
[TBL] [Abstract][Full Text] [Related]
16. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma.
Cheal SM; Xu H; Guo HF; Patel M; Punzalan B; Fung EK; Lee SG; Bell M; Singh M; Jungbluth AA; Zanzonico PB; Piersigilli A; Larson SM; Cheung NV
Theranostics; 2018; 8(18):5106-5125. PubMed ID: 30429889
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution and Tumor Uptake of
Izquierdo-Sánchez V; Muñiz-Hernández S; Vázquez-Becerra H; Pacheco-Yepez J; Romero-Piña ME; Arrieta O; Medina LA
Molecules; 2018 Nov; 23(12):. PubMed ID: 30501113
[TBL] [Abstract][Full Text] [Related]
18. Panitumumab-DOTA-
Facca VJ; Cai Z; Gopal NEK; Reilly RM
Mol Pharm; 2022 Oct; 19(10):3652-3663. PubMed ID: 35926098
[TBL] [Abstract][Full Text] [Related]
19. Biodistribution, Pharmacokinetics, and Dosimetry of
Nicolas GP; Mansi R; McDougall L; Kaufmann J; Bouterfa H; Wild D; Fani M
J Nucl Med; 2017 Sep; 58(9):1435-1441. PubMed ID: 28450554
[TBL] [Abstract][Full Text] [Related]
20. [
Lau J; Kwon D; Rousseau E; Zhang Z; Zeisler J; Uribe CF; Kuo HT; Zhang C; Lin KS; Bénard F
Mol Pharm; 2019 Nov; 16(11):4688-4695. PubMed ID: 31545614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]